Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH)
This panel provided expert opinions on the clinical use of and best practices for treatment titration and management of expected SEs for oral selexipag. Insights are valuable for developing standardized clinical guidelines and best practices, as well as ensuring personalized treatment to improve patient care.
Authors
- Paul Strachan
- Daisy Bridge
- Richard Perry (ORCID: https://orcid.org/0000-0001-8790-3170)
- Naomi Habib (ORCID: https://orcid.org/0009-0006-3388-0616)
- Michelle Cho
- Sheryl Wu (ORCID: https://orcid.org/0000-0001-8314-4787)
- Jennalyn D. Mayeux
- Medi Stone
- Jeremy A. Mazurek (ORCID: https://orcid.org/0000-0002-3332-0102)
- Gurinderpal Doad (ORCID: https://orcid.org/0000-0002-3245-6235)
- Luis Val-Marañes
- J.W. McConnell
- Charlotte Oswald
- Christina K. Benninger
Institutions
- Johnson & Johnson (United States) (US)
- Norton Healthcare (US)
- University of Utah (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- Adelphi Group (United Kingdom) (GB)
- St. Francis Hospital (US)
- Thomas University (US)
Publication Details
- Journal
- Pulmonary Pharmacology & Therapeutics
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1016/j.pupt.2025.102406
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00